Aileron Therapeutics (ALRN)
(Delayed Data from NSDQ)
$2.75 USD
-0.02 (-0.72%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $2.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALRN 2.75 -0.02(-0.72%)
Will ALRN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALRN
Are Medical Stocks Lagging Sensus Healthcare (SRTS) This Year?
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
ALRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock
Other News for ALRN
Aileron Therapeutics initiated with bullish view at Brookline
Aileron Therapeutics Announces New Interim CFO Appointment
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024
Aileron Therapeutics GAAP EPS of -$0.86 beats by $0.16